- Home
- EYPT vs UAMY Comparison
EYPT vs UAMY Comparison
Compare EYPT & UAMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYPT | UAMY |
|---|---|---|
| Founded | 1987 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Metal Fabrications |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2005 | 1997 |
Fundamental Metrics
Financial Performance| Metric | EYPT | UAMY |
|---|---|---|
| Price | $12.55 | $7.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $31.80 | $9.44 |
| AVG Volume (30 Days) | 941.4K | ★ 9.8M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,539,000.00 | ★ $39,257,708.00 |
| Revenue This Year | N/A | $219.89 |
| Revenue Next Year | $3,115.57 | $104.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 162.80 |
| 52 Week Low | $8.37 | $1.94 |
| 52 Week High | $19.11 | $19.71 |
Technical Indicators
Market Signals| Indicator | EYPT | UAMY |
|---|---|---|
| Relative Strength Index (RSI) | 48.33 | 37.04 |
| Support Level | $12.58 | $5.87 |
| Resistance Level | $14.73 | $8.38 |
| Average True Range (ATR) | 0.75 | 0.71 |
| MACD | -0.02 | -0.19 |
| Stochastic Oscillator | 48.53 | 10.97 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About UAMY United States Antimony Corporation
United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has two operating segments: antimony and zeolite. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the Domestic, Canada, and Mexico, of which the vast majority of its revenue comes from the Domestic.